The efficacy outcomes observed in our study are in line with those reported in the pivotal BOLERO-2 trial, which demonstrated a significant improvement in PFS with the addition of everolimus to exemestane in postmenopausal women with HR+/HER2− advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. Here, CYP19A1 is linked to breast carcinoma.